Skip to content

Study of an Ayurvedic Medicine Nagar Shallaki Vati for relief from painful periods.

Efficacy of Nagar-Shallaki Vati in The Management of Kashtartava (Primary Dysmenorrhea) - Open Labelled Randomised Standard Control Clinical Trial. - nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111669
Enrollment
40
Registered
2026-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Sponsors

Institute of Teaching & Research in Ayurveda Jamnagar Gujarat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Married or Unmarried females of age group 15 to 30 years. Regular menstrual cycle ranging from 21 days to 35 days. History of painful menstruation for at least two consecutive menstrual cycles with Visual Analogue Scale score more than 4. Women with Haemoglobin is greater than and equal to 8 grams per deciliter. Patient willing to participate in study.

Exclusion criteria

Exclusion criteria: Cases of secondary dysmenorrhea with pelvic pathology. Patients with fibroid uterus, endometriosis, adenomyosis, abnormal uterine bleeding, pelvic inflammatory disease, ovarian cyst, or cervicitis Patients with congenital anomalies of the reproductive tract. Patients with systemic diseases like Diabetes Mellitus with a Random Blood Sugar level of more than 140 miligrams per deciliter and Hypertension with a Blood Pressure of more than 150 by 90 mmHg and Anaemia with a Haemoglobin level of less than 8 grams per deciliter. Patients on hormonal therapy, contraception, and intra uterine contraceptive device. Patients with surgical and malignant condition.

Design outcomes

Primary

MeasureTime frame
It is expected that trial drugs will reduce the pain during menstruation that will be assessed by VAS ScoreTimepoint: It is expected that trial drugs will help in the reduction in pain while menstruation in 8 weeks.

Secondary

MeasureTime frame
Changes in associated symptoms related to Primary Dysmenorrhea that is Nausea, Vomiting, Constipation & Headache. Changes in the blood flow of uterus by Colour Doppler study. Changes in Uterine peristalsis. Timepoint: 60 Days

Countries

India

Contacts

Public ContactDr.Ramila bhinde

Institute of Teaching & Research in Ayurveda Jamnagar Gujarat

grishmabams@gmail.com9427753900

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026